A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Exenatide (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DURATION 7
- Sponsors AstraZeneca
- 02 Jan 2019 Primary endpoint (Change in HbA1c From Baseline to Week 28) has been met as per results published in the European Clinical Trials Database Trial Registry
- 02 Jan 2019 Results published in the European Clinical Trials Database Trial Registry
- 05 Oct 2018 Results assessing the efficacy and safety of exenatide once weekly across 10 comparator-controlled studies from the DURATION clinical programme (n=2251) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes